Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at a medication called QAW039 compared to a placebo (a dummy treatment with no active ingredient) in people with eczema (also called atopic dermatitis). A total of 76 people were assigned to receive QAW039 and 27 people received the placebo. Of those, 63 people in the QAW039 group and 18 in the placebo group completed the study. The trial's main focus was measuring changes in eczema severity using a scoring system called the Eczema Area and Severity Index (EASI), which rates how much of the skin is affected and how severe the signs are, on a scale from 0 (no disease) to 72 (most severe). The reported data shows that, for the primary outcome — the change in EASI score from the start of the trial — the QAW039 group had an average change of −8.65 points, while the placebo group had an average change of −6.95 points. On this scale, a negative number means the score went down from where it started (i.e., lower severity at the end compared to the beginning). For the secondary outcomes, which also measured EASI score changes at different time points during the study, the reported data shows figures of −6.22 (QAW039) versus −5.89 (placebo), and −7.49 (QAW039) versus −5.61 (placebo). No further breakdown of these time points was provided in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Eczema Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with atopic dermatitis (eczema), confirmed by having itchy skin in the past 12 months plus at least three of the following: eczema in skin folds (like behind the knees or inside the elbows), a personal history of asthma or hay fever, generally dry skin in the past year, eczema starting before age 2, or visible eczema in skin fold areas now.
- Your eczema is rated as moderate to severe based on a scoring system called the EASI (score of 15 or higher), and your condition is currently stable — meaning you are not in the middle of a sudden, severe flare-up.
- You have previously tried prescription creams or ointments (such as steroid creams) at least once, or you were unable to use them due to side effects or other reasons, and you are a candidate for or have already received treatment that works throughout the whole body (such as pills or injections).
Who may not be able to join:
- You have had a known allergic reaction to any of the study medications (including local anaesthetic) or to similar types of drugs (confirm with trial site).
- You have had a severe, life-threatening allergic reaction in the past, such as anaphylactic shock, or serious asthma events (such as needing a breathing tube, experiencing respiratory arrest, or being hospitalised for asthma in the last 3 months), or seizures caused by asthma.
- You have a history of significant heart rhythm problems, or an abnormal heart tracing (ECG) result at your screening appointment.
- You have a history of a heart condition called Long QT syndrome, or your heart's electrical timing measurement (QT interval) was above a certain level at screening.
- You have used prescription skin treatments (such as steroid creams, antibiotic creams, or similar) within two weeks before the study starts — though a short course of mild steroid cream may be allowed for a sudden flare during that period (confirm with trial site).
- You have recently had certain whole-body treatments such as light therapy (phototherapy), antihistamine tablets, or immune-suppressing medications (such as cyclosporine or similar drugs).
- You are receiving allergy immunotherapy (desensitisation treatment) and either started it or had a significant change to it within one month before joining the study.
- You are taking high doses of certain cholesterol-lowering medications (statins) above specific limits (confirm with trial site for exact doses).
- You have had a lot of UV light exposure (including sunbeds or tanning) in the three weeks before the study starts, or you plan to do so during the treatment period.
- You have a history of raised, thickened scarring (hypertrophic scarring).
- Your body mass index (BMI — a measure of weight relative to height) is below 17 or above 40.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change From Baseline in Eczema Area and Severity Index (EASI)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.